| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/NEUR.1995.0052 |
| P698 | PubMed publication ID | 8846237 |
| P50 | author | Kaj Blennow | Q28321550 |
| Eugeen Vanmechelen | Q30533725 | ||
| P2093 | author name string | Davidsson P | |
| Skoog I | |||
| Hesse C | |||
| Palmertz B | |||
| Andreasson LA | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| dementia | Q83030 | ||
| P304 | page(s) | 433-442 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Experimental Neurology | Q5421127 |
| P1476 | title | A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. | |
| P478 | volume | 4 |
| Q35196321 | Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein |
| Q60313667 | Alzheimer's disease |
| Q41518367 | Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases |
| Q51988901 | Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. |
| Q24650667 | Biomarkers of Alzheimer's disease |
| Q41765446 | Both total and phosphorylated tau are increased in Alzheimer's disease |
| Q42091274 | CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder. |
| Q37165604 | CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease |
| Q34113001 | CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease |
| Q48762266 | Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia |
| Q47595482 | Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations |
| Q48171419 | Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. |
| Q42912092 | Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study |
| Q35631400 | Cholinesterase inhibitors and vascular dementia: another string to their bow? |
| Q34456110 | Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid |
| Q35540384 | Comparison between Alzheimer's disease and vascular dementia: Implications for treatment |
| Q34558884 | Dementia prevention, intervention, and care. |
| Q33971355 | Diagnostic approaches to Alzheimer's disease |
| Q48253639 | Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease |
| Q38570242 | How many biomarkers to discriminate neurodegenerative dementia? |
| Q35540392 | Hypertension, hypertension-clustering factors and Alzheimer's disease |
| Q35857978 | Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay |
| Q44340838 | Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease |
| Q46914423 | Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. |
| Q30953178 | MRI and CSF studies in the early diagnosis of Alzheimer's disease |
| Q53215966 | NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. |
| Q53245453 | Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. |
| Q53225650 | No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. |
| Q28214125 | Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease |
| Q51553331 | Protein phosphorylation studies of cerebral spinal fluid for potential biomarker development |
| Q30813216 | Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. |
| Q37845820 | Tau and p-tau as CSF biomarkers in dementia: a meta-analysis |
| Q57897029 | Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work |
| Q46788633 | Tau proteins in the temporal and frontal cortices in patients with vascular dementia. |
| Q33950413 | The role of cerebral ischemia in Alzheimer's disease |
| Q53215353 | The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. |
| Q47964631 | Update on Vascular Dementia |
Search more.